Narrative synthesis on CRISPR-Cas systems for multidrug-resistant bacterial infections
CRISPR Gene Editing Could Finally Beat Superbug Infections
This narrative synthesis reviews preclinical evidence on CRISPR-Cas systems for multidrug-resistant bacterial infections. It finds that phag…
A new review shows CRISPR gene editing can target and destroy superbugs that resist standard antibiotics, offering a fresh weapon against th…
Genomic analysis of ceftazidime/avibactam-resistant Klebsiella pneumoniae isolates from transplant unit
Italian study finds resistant bacteria in transplant unit carry multiple concerning genes
A retrospective cohort study of 14 clinical isolates from an Italian transplant unit found most ceftazidime/avibactam-resistant Klebsiella p…
Resistant bacteria in an Italian transplant unit carry multiple drug-resistance genes and traits that help them cause disease.
Engineered bacteriophage systems show potential framework for treating multidrug-resistant bacterial infections
Can engineered viruses help fight superbugs? A new review maps a path forward
A systematic review discusses advances in engineered bacteriophage therapeutic systems for multidrug-resistant pathogens.
Engineered viruses paired with advanced imaging offer a new way to fight dangerous superbugs that no longer respond to standard antibiotics.
Questions about Multidrug-Resistant Bacterial Infections
Can bacteriophage systems be used to treat multidrug-resistant bacterial infections?
Yes, engineered bacteriophage systems can treat multidrug-resistant infections by targeting specific bacteria, disrupting resistance genes, and overcoming bacterial defenses through advanced genetic modifications.
Full answer →Are CRISPR-Cas systems a potential treatment for multidrug-resistant bacterial infections?
CRISPR-Cas systems are a promising new treatment for multidrug-resistant infections because they can precisely target and destroy specific resistance genes in bacteria, potentially restoring the effectiveness of existing antibiotics.
Full answer →